Blog

Tel Aviv, Israel / Vancouver, Canada, March 19, 2024 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY) (“Clearmind” or the “company”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced that it has been granted divisional patent approval by the China National Intellectual Property Administration. The divisional patent approval, previously announced, grants Clearmind a broader claim than patent application. Allowed claims directed to using a primary amine aminoindan compound to regulate a binge behavior. Covers primary amine aminoindan compounds besides 5-methoxy-2-aminoindan (MEAI), the company’s innovative psychedelic molecule. This latest patent builds upon Clearmind’s broad IP…

In a recent digital conversation with ex-CNN host Don Lemon, now shared widely across the internet, Tesla and SpaceX chief Elon Musk candidly discussed his mental health management strategies, including the use of a prescribed ketamine treatment, asserting its positive impact on his professional performance and, by extension, Tesla’s investor value. During this revealing interview, Musk addressed a variety of topics ranging from politics and social media moderation on X (formerly Twitter) to his multifaceted role at the helm of several cutting-edge companies. Musk highlighted the critical importance of operational efficiency for investor confidence, especially within the high-stakes environment of…

Toronto, Ontario–(Newsfile Corp. – March 18, 2024) –  Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) (“Red Light Holland” or the “Company”), a company engaged in the production, growth and sale of functional mushrooms and mushroom home grow kits in North America and Europe and a premium brand of psilocybin truffles to the legal, recreational market within the Netherlands, is excited to announce a significant milestone for its subsidiary, Happy Caps, as its products are now available in over 270 retail stores across Canada, a 100% increase of points of sale since the Company’s press release dated August…

SARASOTA, FL, March 18, 2024 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that it has filed a provisional patent application titled ‘Methods and Combinations for Managing Pain’ with the United States Patent and Trademark Office (USPTO). The patent application includes protection for the Company’s SP-26 implantable drug delivery system for a novel time-released, dose-controlled formulation of ketamine, initially targeted for fibromyalgia. Silo believes that implantable drug delivery may be well-suited for chronic pain management. “Our SP-26 implant technology is designed to deliver…

Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced participation in the upcoming Public Ventures Discovery Day on March 19, 2024 in Dallas, TX. Doug Drysdale, Chief Executive Officer of Cybin will participate in a fireside chat at the event and will be available to meet attendees during breakout sessions. Public Ventures Discovery Day Date:   Tuesday, March 19, 2024 Presentation:   3:05 PM CT Location:   Pecan Room, Old Parkland, 3819 Maple Avenue, Dallas TX 75219 A video replay…